Mesoblast/$MESO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Mesoblast
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Ticker
$MESO
Sector
Primary listing
Employees
81
Headquarters
Melbourne, Australia
Website
Mesoblast Metrics
BasicAdvanced
$2B
-
-$0.08
0.76
-
Price and volume
Market cap
$2B
Beta
0.76
52-week high
$22.00
52-week low
$8.52
Average daily volume
220K
Financial strength
Current ratio
1.991
Quick ratio
1.719
Long term debt to equity
11.938
Total debt to equity
21.451
Interest coverage (TTM)
-2.87%
Profitability
EBITDA (TTM)
-58.182
Gross margin (TTM)
-132.22%
Net profit margin (TTM)
-593.92%
Operating margin (TTM)
-363.08%
Effective tax rate (TTM)
-0.32%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-5.37%
Return on equity (TTM)
-18.95%
Valuation
Price to revenue (TTM)
1,091.369
Price to book
5.16
Price to tangible book (TTM)
120.42
Price to free cash flow (TTM)
-370.317
Free cash flow yield (TTM)
-0.27%
Free cash flow per share (TTM)
-0.042
Growth
Revenue change (TTM)
191.39%
Earnings per share change (TTM)
-5.09%
3-year revenue growth (CAGR)
18.98%
10-year revenue growth (CAGR)
-1.38%
3-year earnings per share growth (CAGR)
-14.17%
10-year earnings per share growth (CAGR)
-11.89%
What the Analysts think about Mesoblast
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Bulls say / Bears say
In May 2025, Mesoblast was granted seven years of FDA orphan-drug exclusivity for Ryoncil, plus 12 years of biologic exclusivity until December 2036, and its patents run through 2044, establishing a significant competitive barrier (GlobeNewswire)
Mesoblast posted US$17.2 million in cell therapy revenue for FY25, up 191% year over year, boosted by the U.S. launch of Ryoncil, which delivered US$11.3 million in net sales — evidence of strong market adoption (GlobeNewswire)
Analysts value Ryoncil’s lifetime clinical benefit at US$3.2 to US$4.1 million per patient, supporting a premium price and positive reimbursement prospects in its rare disease context (GlobeNewswire)
The U.S. pediatric SR-aGvHD patient pool is only about 375 annually, limiting Ryoncil’s peak-year revenue unless approved for adult use (GlobeNewswire)
Although Mesoblast had $162 million in cash as of June 30, 2025, its $50 million net operating cash burn for FY25 raises concerns about funding if revenue slows (GlobeNewswire)
The option to issue up to $50 million in convertible notes highlights ongoing capital requirements and carries a risk of shareholder dilution (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Mesoblast Financial Performance
Revenues and expenses
Mesoblast Earnings Performance
Company profitability
Mesoblast News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mesoblast stock?
Mesoblast (MESO) has a market cap of $2B as of November 06, 2025.
What is the P/E ratio for Mesoblast stock?
The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of November 06, 2025.
Does Mesoblast stock pay dividends?
No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Mesoblast dividend payment date?
Mesoblast (MESO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mesoblast?
Mesoblast (MESO) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.